Login to Your Account



Durata's Dalbavancin Hits the Home Stretch

By Mari Serebrov


Wednesday, April 20, 2011
With a new road map in hand, Durata Therapeutics Inc. has its lead candidate, dalbavancin, back on course for what it hopes is the final lap to FDA approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription